|Bid||14.22 x 1300|
|Ask||14.23 x 2200|
|Day's Range||13.87 - 14.52|
|52 Week Range||2.00 - 24.00|
|Beta (3Y Monthly)||3.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.33|
VK2809 Treatment Leads to Rapid Reduction in Steatosis, Inflammation and Liver Size in Mouse Model of Glycogen Storage Disease Type Ia (GSD Ia) SAN DIEGO , Oct. 8, 2018 /PRNewswire/ -- Viking Therapeutics, ...
HENDERSON, NV / ACCESSWIRE / October 5, 2018 / Liver cancer incidence has more than tripled since 1980. Liver cancer death rates have increased by almost 3% per year since 2000. More than 700,000 people ...
In October, of the seven analysts covering Viking Therapeutics (VKTX), one has given its stock a “strong buy” rating, and six have given it “buy” ratings. The mean rating for Viking stock is 1.86, and its target price is $32.33, implying an upside potential of 112.1% over its closing price of $15.24 on October 2. In comparison, peers BeyondSpring (BYSI) and Ra Pharmaceuticals (RARX) have mean ratings of 2 and 1.83, respectively, and target prices of $53.83 and $22.17, respectively.
Presentation to Highlight Positive 12-Week Data for Novel, Liver-Selective Thyroid Receptor Beta Agonist in Patients with Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol SAN DIEGO , Oct. ...
Viking Therapeutics’ (VKTX) product candidate VK2809 is undergoing a Phase 2 trial for the treatment of patients with hypercholesterolemia and fatty liver disease. In October 2017, the company announced positive final results from an eight-week study of the drug for the treatment of nonalcoholic steatohepatitis (or NASH). In this study, VK2809 showed significant reductions in liver triglyceride content and total liver lipid content and significant changes in the expression of genes associated with NASH development and progression.
Clinical-stage biopharmaceutical company Viking Therapeutics (VKTX) is focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics believes that VK5211 could have potential benefits for patients with muscle loss in indications such as joint replacement or muscle wasting disorders. In a Phase 2 study, the drug showed statistically significant and dose-dependent increases in lean body mass.
Nonalcoholic steatohepatitis (or NASH) focused stocks have been garnering more investor interest so far in 2018. In this series, we’ll analyze three companies with focused NASH pipelines: Intercept Pharmaceuticals (ICPT), Viking Therapeutics (VKTX), and Madrigal Pharmaceuticals (MDGL).
On October 1, 2018, Viking Therapeutics, Inc. (VKTX) announced that results from the Phase 2 clinical trial of VK5211 in patients with hip fracture were presented at the 2018 American Society for Bone and Mineral Research (ASBMR) Annual Meeting. This was a multicenter, randomized, double blind, placebo controlled trial that enrolled a total of 108 subjects (83 women and 25 men) age ≥ 65 years of age who have suffered a hip fracture within the past three to seven weeks. Subjects were administered placebo or 0.5 mg, 1.0 mg, or 2.0 mg of VK5211 once-daily for 12 weeks (NCT02578095).
Viking Therapeutics Inc. shares surged 4% in premarket trade Monday, after the company reported positive results in a mid-stage trial of a treatment for broken hips. The company said its Phase 2 trial of VK5211 in patients who recent suffered a hip fracture met its primary goal of showing statistically significant increases in lean body mass as compared with placebo. The trial also found increases in 6-minute walk distance, a greater than 20-meter improvement over placebo at the highest dose. In September, Viking posted positive results from a trial of a non-alcoholic fatty liver disease treatment, sending its stock up 87%. Shares have gained 329% in 2018 so far, while the S&P 500 has gained 9%.
NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Major U.S. markets finished flat on Friday. For the third quarter, the S&P 500 Index jumped over 7 percent, its best quarter since 2013, while the Dow Jones ...
Study Achieves Primary Endpoint, Demonstrating Statistically Significant, Dose-Dependent Increases in Lean Body Mass Ranging from 4.8% to 9.1% Following Treatment with VK5211 Positive Body Composition ...
Biotech shares saw further momentum last week, following up on the gains of the previous two weeks. Will the momentum continue in the upcoming week? Here are the catalytic events that could drive the sector. ...
Here's what has made the best healthcare stocks of this young century the best -- and why some stocks could be poised to join the club.
The stars are aligning for several biotech stocks. Most often occurring in obese or glucose-intolerant people, Nonalcoholic Steatohepatitis or NASH is quickly increasing in prevalence. For those nations with fatty diets, the prevalence of NASH are estimated to be as much as 20% of the total population.
SAN DIEGO , Sept. 26, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Tilray's wild ride may be starting to slow down, but Amarin Corp. and Viking Therapeutics are just getting started. Here's why.
The Phase 2 trial was a randomized, double blind, placebo controlled study where patients were treated once daily or every other day with 10 mg VK2809 or once daily with placebo for 12 weeks followed by four weeks off drug. While the primary endpoint of the study was change in LDL cholesterol, the most important endpoints were the secondary ones related to NAFLD that evaluated changes in liver fat content, inflammatory markers, and histological changes.
SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its public offering of 9,500,000 shares of its common stock at a price to the public of $18.50 per share. Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes. The offering is expected to close on or about September 25, 2018, subject to satisfaction of customary closing conditions.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...